Since authors previously demonstrated that c-Src activation led to Cripto-1 over-expression in EGFR mutant NSCLC, contributing to the intrinsic resistance to EGFR-TKIs, the ongoing trial aims to define the MTD of dasatinib, administered in combination with osimertinib, and to assess the role of Cripto-1 protein as predictive biomarkers of response (Table 3; NCT02954523). Here, EGFR is linked to non-small cell lung carcinoma.